Skip to main content
. 2004 Nov 15;143(8):952–959. doi: 10.1038/sj.bjp.0706019

Figure 2.

Figure 2

Ability of the I2-site ligand 2-BFI (14 mg kg−1 i.p.) or the MAO inhibitors, moclobemide (10 mg kg−1 i.p.) and lazabemide (10 mg kg−1 i.p.) to potentiate L-DOPA (10 mg kg−1 i.p.)-induced contraversive rotations in rats bearing a unilateral 6-OHDA lesion. (a, b) Total number of rotations over 240 min are shown. *P<0.05 indicates a statistically significant difference between drug+L-DOPA versus vehicle+L-DOPA using either a paired t-test (a) or Dunnett's test after a significant two-way ANOVA (b). (c, d) Animals were administered test drugs in conjunction with benserazide (15 mg kg−1) at time T-30 min, with 10 mg kg−1 L-DOPA being given 30 min later at time T0. In (c), *P<0.05 indicates a statistically significant difference between 2-BFI+L-DOPA versus vehicle+L-DOPA (paired t-test; after a significant 2-way ANOVA). In (d), *P<0.05, and **P<0.01 indicate a statistically significant difference between lazabemide+L-DOPA versus vehicle+L-DOPA; +P<0.05 indicates a statistically significant difference between moclobemide+L-DOPA versus vehicle+L-DOPA (Dunnett's test after a significant two-way ANOVA). Data are mean±s.e.m. (n=7). Abbreviations: Laz, lazabemide. Moc, moclobemide. Veh, vehicle.